CRO services in NASH
Accelerate your drug development by exploring clinical endpoints in our
validated and biopsy-confirmed mouse models of NASH
Publications
- THR-ß agonism improves disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis
- Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis
- Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
- Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis
- Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis
- Activation of adenosine monophosphate-activated protein kinase reduces the onset of diet-induced hepatocellular carcinoma in mice
- Incretin combination therapy for the treatment of non-alcoholic steatohepatitis
- The selective peroxisome proliferator‐activated receptor gamma modulator CHS‐131 improves liver histopathology and metabolism in a mouse model of obesity and nonalcoholic steatohepatitis
- Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy
- Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development
- Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Posters
- Metabolic, biochemical, histopathological, and transcriptomic effects of semaglutide and lanifibranor treatment in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
- Characterization of disease progression and pharmacological intervention in the GAN diet-induced obese mouse model of NASH with advanced fibrosis and hepatocellular carcinoma
- Coadministration of a GLP-1 receptor agonist with an FXR agonist and ACC inhibitor reverses nonalcoholic steatohepatitis in diet-induced and biopsy-confirmed mice
- Coadministration of a GLP-1/Glucagon receptor agonist with an FXR agonist and ACC inhibitor reverses nonalcoholic steatohepatitis in diet-induced and biopsy-confirmed mice
- Obeticholic acid exerts anti-inflammatory action and suppress expansion of hepatic immune cell populations in the Gubra biopsy-confirmed DIO-NASH mouse model
- A comparison of histological and transcriptional markers of non-alcoholic steatohepatitis (NASH) in man and mouse
- MET409, a potent, non-bile acid sustained FXR agonist, improves NAFLD Activity Score and exerts anti-fibrotic action in a diet-induced obese mouse model of biopsy-confirmed NASH with fibrosis
- Effect of elafibranor treatment and dietary intervention in the Gubra Amylin NASH (GAN) diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- Histological scoring of nonalcoholic fatty liver disease using deep learning
- Effect of OCA treatment on metabolic parameters, hepatic pathology and NAFLD Activity Score including Fibrosis Stage in female and male biopsy-confirmed DIO-NASH mice
Publications
- Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
- Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH
- Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis
- Activation of adenosine monophosphate-activated protein kinase reduces the onset of diet-induced hepatocellular carcinoma in mice
- Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
- INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy
- Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development
- Mouse models of nonalcoholic steatohepatitis in preclinical drug development
Posters
- Histological scoring of nonalcoholic fatty liver disease using deep learning
- Obeticholic acid improves histological, biochemical and gene expression profiles in Gubra AMLN mice with diet-induced and biopsy-confirmed NASH
- A3907, a novel inhibitor of bile acid transport in the intestine and the kidney, improves markers of metabolic and hepatic pathology and reduces NAFLD activity score and fibrosis stage in a diet-induced and biopsy-confirmed mouse model of nonalcoholic steatohepatitis
Publications
- Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
- Mouse models of nonalcoholic steatohepatitis in preclinical drug development
- Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development
AI-assisted NASH histopathology using GHOST
At Gubra, we have developed the deep learning-based app GHOST (Gubra Histopathological Objective Scoring Technology) to automatically perform complete NAFLD Activity Score (NAS) and Fibrosis Staging in liver biopsies with additional quantitative metrics.
Gubra in vivo study approach
Our DIO-NASH mice are always ready and available for rapid onset of efficacy studies.
Pre- and post-liver biopsies allow for stratification of disease severity at baseline and improves detection of drug treatment efficacy.
All animals enrolled into study groups demonstrate histology-proven hepatosteatosis and fibrosis.
Related Links:
Main offerings
- Metabolic assessment (body weight, adiposity, food intake, glycemic control and glucose tolerance)
- Biochemical assessment for plasma lipids and liver biomarkers
- Biochemical assessment for hepatic lipid, inflammation and collagen content
- Histomorphomtric assesment for hepatic steatosis, inflammation, hepatocellular ballooning and fibrosis
- Histopathological scoring for NAFLD Activity Score and Fibrosis Stage
- Deep learning AI
- RNA sequencing and bioinformatics
- Flow cytometry
Get in touch
Please get in touch if you are interested in discussing how to get your study started.
Michael Feigh
Director
mfe@gubra.dk
+45 2382 9493
